Nasopharyngeal Carcinoma Diagnosis
Nasopharyngeal Carcinoma Diagnosis
A biopsy through the nose confirms the diagnosis; MRI of the nasopharynx and skull base stages it. Plasma EBV DNA adds something no scan can — a measurement of how much tumour is present.
Endoscopy: where the diagnosis is made
Nasopharyngoscopy is a clinic procedure. A thin flexible or rigid endoscope is passed along the floor of the nose, topical anaesthetic is used, and the nasopharynx is inspected from both sides. The examination takes minutes, and it is the step that turns a neck lump into a diagnosis rather than a referral.
What the examiner looks for is a mass on the side wall or roof of the nasopharynx, most often in the fossa of Rosenmüller. Early tumours can be subtle — a slight asymmetry, an area that bleeds on contact, a patch of altered mucosa — and an asymmetry is enough to justify a biopsy. A biopsy is taken from the primary site at the same sitting, and it is the primary tumour that must be sampled: a biopsy of the neck node alone confirms that the node is malignant but leaves the diagnosis incomplete, which changes the treatment plan.
MRI, not CT, for the primary tumour
Contrast-enhanced MRI of the nasopharynx, skull base and neck is the imaging standard for this disease, and the reason is specific. The questions that decide the stage are soft-tissue questions — has the tumour reached the parapharyngeal space, has it eroded the skull base, has it followed the nerves towards the cavernous sinus — and MRI answers them where CT is ambiguous.
The MRI also defines the radiotherapy target. Because the treatment is radiotherapy, the imaging is not only a staging tool but the plan itself: the radiation oncologist contours the tumour and the at-risk tissue directly onto the MRI. A study done elsewhere on a CT, or an MRI without the sequences needed for skull-base assessment, often has to be repeated here. PET-CT is used in addition, not instead, and its main purpose is to detect distant spread in bone, lung or liver in patients with advanced nodal disease.
Plasma EBV DNA: what it adds that imaging cannot
Epstein-Barr virus DNA can be measured in a blood sample, and in nasopharyngeal carcinoma it is released by the tumour cells themselves. That makes it a tumour marker in the truest sense: not a proxy for the tumour but a product of it, and one that reflects tumour burden rather than anatomy.
It has three uses. At diagnosis it is measured as a baseline and has prognostic value — a high viral load predicts a higher risk of recurrence independently of stage. During treatment the rate at which it falls is a measure of how well the tumour is responding. After treatment a rising level is often the earliest signal of recurrence, detectable months before a scan shows anything, which is why it is measured at each follow-up visit. In endemic regions it is also used to screen people without symptoms, which is discussed on the screening page.
Reading the pathology report
The pathology report does two jobs: it confirms the diagnosis and it places the tumour in a WHO group, which predicts behaviour and radiotherapy response.
- WHO type I — keratinizing squamous cell carcinoma. Separately classed because its behaviour differs from the endemic types.
- WHO type II — non-keratinizing, differentiated. Strongly EBV-associated and radiosensitive.
- WHO type III — non-keratinizing, undifferentiated. The classic endemic type, the most radiosensitive, and the one most likely to present as a neck node.
- EBV status on the tissue — usually reported as viral RNA or protein, and used to confirm the association.
- Other types — basaloid squamous carcinoma or a salivary gland-type tumour, which are managed differently.
If the report says only squamous cell carcinoma without a WHO group, or does not mention EBV status, it is worth asking. The group affects the treatment intensity and the prognosis, and the EBV result is what distinguishes an endemic nasopharyngeal carcinoma from a keratinizing cancer arising in the same place, which behaves far less favourably.
Staging: the boundaries that change the plan
Staging follows the AJCC system, but in this disease three boundaries do most of the work:
- The parapharyngeal space — the fat and muscle beside the nasopharynx. Involvement moves a tumour from T1 to T2, and it also means the radiotherapy target must extend laterally around the jaw.
- The skull base — erosion of the bone beneath the nasopharynx makes it T3. It is the boundary between a straightforward plan and one built around critical structures.
- Inside the skull, the cranial nerves, the orbit and the lower throat — any of these makes it T4, and they push the dose limits for the brain, the optic nerves and the temporal lobes to the centre of the planning discussion.
Nodes are staged separately, and the N categories in nasopharyngeal carcinoma differ from those used for other head and neck cancers because nodal involvement is so common and so prognostically important. Distant spread — most often bone, lung or liver — is looked for with PET-CT in patients with advanced neck disease, and it separates Stage IVB from the rest.
Arranging the work-up from abroad
Most of the diagnostic pathway can be begun in your own country, but three parts usually need to be done or repeated here, and knowing which saves a wasted trip.
The biopsy can be reviewed from the slides and the report, but if the tumour was diagnosed from a neck node alone, the primary still has to be found and sampled. MRI should include the nasopharynx, skull base and neck with contrast and the sequences needed to assess skull-base invasion; a scan done elsewhere without those sequences will be repeated. And baseline assessments before radiotherapy — audiometry, a dental assessment, thyroid function and, where relevant, an eye examination — are part of the preparation for treatment rather than optional extras, because they determine what has to be protected during planning.